Can liver cancer cause hypertension (high blood pressure)?

Can Liver Cancer Cause High Blood Pressure?

Liver cancer itself rarely causes hypertension directly, but the underlying cirrhosis and portal hypertension that typically accompany hepatocellular carcinoma (HCC) are distinct from systemic arterial hypertension. The relationship between liver cancer and blood pressure is complex and involves multiple mechanisms.

Direct Paraneoplastic Hypertension (Rare)

While uncommon, HCC can cause true systemic hypertension as a paraneoplastic syndrome through overproduction of renin-angiotensin system components:

• Ectopic renin production: Malignant hepatocytes can produce and secrete active renin, leading to markedly elevated plasma renin activity (up to 6.05 ng/mL/h) and angiotensin levels 1, 2
• Excessive angiotensinogen synthesis: HCC can produce 8-10 fold increases in plasma angiotensinogen concentrations 2
• This mechanism is documented but represents a rare paraneoplastic manifestation of HCC

Portal Hypertension vs. Systemic Hypertension

It is critical to distinguish portal hypertension from systemic arterial hypertension—these are separate entities:

• Portal hypertension (elevated pressure in the portal venous system) is a common feature of the cirrhosis underlying most HCC cases 3
• Portal hypertension is assessed by hepatic venous pressure gradient (HVPG ≥10 mmHg defines clinically significant portal hypertension) 4, 5
• This does NOT cause elevated systemic blood pressure readings on a standard blood pressure cuff

Cancer Treatment-Induced Hypertension (Common)

The more clinically relevant concern is treatment-induced hypertension, which affects up to 50% of cancer patients:

High-Risk Therapies for HCC:

• Bevacizumab (used with atezolizumab in first-line HCC treatment): 11-45% incidence of new hypertension 6, 7
• Sorafenib: 7-43% incidence 6
• Lenvatinib: May promote portal hypertension development 8

Mechanisms:

• Inhibition of VEGF reduces nitric oxide production, causing vasoconstriction 6
• Impaired endothelial function and increased peripheral vascular resistance 9, 10
• These effects typically occur within the first month of treatment 6

Clinical Implications

For patients with HCC:

1. Baseline assessment: Measure systemic blood pressure before starting any systemic therapy 11, 7

2. During treatment: Monitor blood pressure regularly, especially in the first month of VEGF inhibitor therapy 6, 12

3. Distinguish the types of hypertension:

   • Portal hypertension requires endoscopic surveillance for varices 3, 11
   • Systemic hypertension requires antihypertensive medication

4. Treatment of systemic hypertension: ACE inhibitors are preferred first-line agents, as they improve endothelial function and may enhance cancer treatment efficacy 6, 7

Important Caveats

• Patients with HCC being considered for bevacizumab-based therapy must undergo esophagogastroduodenoscopy within 6 months to assess and treat esophageal varices due to bleeding risk 11
• The presence of portal hypertension influences surgical candidacy for HCC resection but does not cause systemic hypertension 3
• Cancer patients have higher cardiovascular mortality, making blood pressure control crucial 9, 13

Bottom line: While HCC rarely causes systemic hypertension as a paraneoplastic syndrome, the cancer treatments (particularly VEGF inhibitors) commonly cause it, and the underlying cirrhosis causes portal hypertension—a separate condition requiring different management.